Current treatment and recent clinical research in Alzheimer's disease

Mount Sinai Journal of Medicine

Volumn 77, Issue 1, 2010, Pages 3-16

  Neugroschl, Judith ^a   Sano, Mary ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Amyloid; Antioxidant; Dimebon; Immunotherapy; Receptor for advanced glycation end products; Research; Secretase; Tau; Treatment

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIOXIDANT; ATORVASTATIN; BMS 708163; CAD 106; CONJUGATED ESTROGEN; CORTICOSTEROID; CYANOCOBALAMIN; DIMEBON; DOCOSAHEXAENOIC ACID; ESTROGEN; FOLIC ACID; GALANTAMINE; HERBACEOUS AGENT; HOMOCYSTEINE; MEMANTINE; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PF 04360365; PHYSOSTIGMINE; PLACEBO; PREDNISONE; PYRIDOXINE; RALOXIFENE; RIVASTIGMINE; SELENIUM; SEMAGACESTAT; SIMVASTATIN; TACRINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XALIPRODEN;

ALZHEIMER DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; DRUG MEGADOSE; GASTROINTESTINAL HEMORRHAGE; GINKGO BILOBA; HUMAN; IMMUNOTHERAPY; KIDNEY FAILURE; LIVER CELL DAMAGE; LOW DRUG DOSE; NAUSEA; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PROSTATE CANCER; REVIEW; TREATMENT FAILURE; VOMITING;

ALZHEIMER DISEASE; DRUGS, INVESTIGATIONAL; HUMANS; RESEARCH;

EID: 75649105019     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20165     Document Type: Review

References (126)

1. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88: 1337-1342.
2. Zhu CW, Scarmeas N, Torgan R, et al. Longitudinal study of effects of patient characteristics on direct costs in Alzheimer's disease. Neurology 2006; 67: 998-1005.
3. Alzheimer's Association. 2009 Alzheimer's disease facts and figures. Alzheimers Dement 2009; 5: 234-270.
4. Deutsch JA, Rocklin KW. Amnesia induced by scopolamine and its temporal variations. Nature 1967; 216: 89-90.
5. Fist HS. An evaluation of obstetrical analgesia. Calif Med 1954; 80: 91-94.
6. Drachman DA. Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology 1977; 27: 783-790.
7. Davis KL, Hollister LE, Overall J, et al. Physostigmine: effects on cognition and effect in normal subjects. Psychopharmacology (Berl) 1976; 51: 23-27.
8. Davis KL, Mohs RC. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry 1982; 139: 1421-1424.
9. Mohs RC, Davis BM, Johns CA, et al. Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatry 1985; 142: 28-33.
10. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317-324.
11. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl JMed 2003; 348: 1333-1341.
12. Bauer J, Ganter U, Strauss S, et al. The participation of interleukin-6 in the pathogenesis of Alzheimer's disease. Res Immunol 1992; 143: 650-657.
13. Fillit H, Ding WH, Buee L, et al. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci Lett 1991; 129: 318-320.
14. Griffin WS, Stanley LC, Ling C, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer's disease. Proc Natl Acad Sci U S A 1989; 86: 7611-7615.
15. Matsubara E, Hirai S, Amari M, et al. Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer's-type dementia. Ann Neurol 1990; 28: 561-567.
16. McGeer PL, McGeer E, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer's disease. Lancet 1990; 335: 1037.
17. Hayden KM, Zandi PP, Khachaturian AS, et al. Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology 2007; 69: 275-282.
18. Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 2000; 54: 588-593.
19. Van Gool WA, Weinstein HC, Scheltens P, Walstra GJ. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 2001; 358: 455-460.
20. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer's disease progression: a randomized controlled trial. JAMA 2003; 289: 2819-2826.
21. Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004; 62: 66-71.
22. Breitner JC, Haneuse SJ, Walker R, et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 2009; 72: 1899-1905.
23. Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005; 30: 1204-1215.
24. Group AR, Lyketsos CG, Breitner JC, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007; 68: 1800-1808.
25. Meinert CL, McCaffrey LD, Breitner JC. Alzheimer's Disease Anti-Inflammatory Prevention Trial: design, methods, and baseline results. Alzheimers Dement 2009; 5: 93-104.
26. Chakravarti B, Chakravarti DN. Oxidative modification of proteins: age-related changes. Gerontology 2007; 53: 128-139.
27. Nunomura A, Moreira PI, Lee HG, et al. Neuronal death and survival under oxidative stress in Alzheimer's and Parkinson diseases. CNS Neurol Disord Drug Targets 2007; 6: 411-423.
28. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997; 336: 1216-1222.
29. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379-2388.
30. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23-33.
31. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301: 39-51.
32. Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439-1443.
33. Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000; 356: 1627-1631.
34. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A 2001; 98: 5856-5861.
35. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer's disease: preliminary results. Arch Neurol 2005; 62: 753-757. 36. Sparks DL, Connor DJ, Sabbagh MN, et al. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl 2006; 185: 3-7.
36. Sjogren M, Gustafsson K, Syversen S, et al. Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein. Dement Geriatr Cogn Disord 2003; 16: 25-30.
37. Sano M. Multi-center, randomized, double-blind, placebo-controlled trial of simvastatin to slow the progression of Alzheimer's disease. Alzheimers Dement 2008; 4(Suppl 4): T200.
38. Zhou B, Teramukai S, Fukushima M. Prevention and treatment of dementia or Alzheimer's disease by statins: a meta-analysis. Dement Geriatr Cogn Disord 2007; 23: 194-201.
39. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
40. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-1630.
41. Anonymous Council of the MedicalWomen's Foundation. An investigation of menopause in one thousand women. Lancet 1933; 1: 106-108.
42. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer's disease. Arch Intern Med 1996; 156: 2213-2217.
43. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348: 429-432.
44. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 1997; 48: 1517-1521.
45. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA 1993; 269: 2637-2641.
46. Barrett-Connor E, Edelstein S. A prospective study of dehydroepiandrosterone sulfate and cognitive function in an older population: the Rancho Bernardo study. J Am Geriatr Soc 1994; 42: 420-423.
47. Brenner DE, Kukull WA, Stergachis A, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based casecontrol study. Am J Epidemiol 1994; 140: 262-267.
48. DeVoogd T, Nottebohm F. Gonadal hormones induce dendritic growth in the adult avian brain. Science 1981; 214: 202-204.
49. Matsumoto A, Arai Y. Neuronal plasticity in the deafferented hypothalamic arcuate nucleus of adult female rats and its enhancement by treatment with estrogen. J Comp Neurol 1981; 197: 197-205.
50. Sohrabji F, Miranda RC, Toran-Allerand CD. Estrogen differentially regulates estrogen and nerve growth factor receptor mRNAs in adult sensory neurons. J Neurosci 1994; 14: 459-471.
51. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000; 54: 295-301.
52. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000; 283: 1007-1015.
53. Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology 2000; 54: 2061-2066.
54. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004; 291: 2947-2958.
55. Craig MC, Maki PM, Murphy DG. TheWomen's Health Initiative Memory Study: findings and implications for treatment. Lancet Neurol 2005; 4: 190-194.
56. Maki PM, Gast MJ, Vieweg AJ, et al. Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial. Neurology 2007; 69: 1322-1330.
57. Yaffe K, Krueger K, Cummings SR, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry 2005; 162: 683-690.
58. Raloxifene for women with Alzheimer's disease. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT00368459. Accessed November 2009.
59. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer's disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006; 63: 1402-1408.
60. Results from trials of DHA in Alzheimer's disease and age-related cognitive decline. Available at: http:// www.alz.org/icad/2010 release 071209 1am b.asp. Accessed November 2009.
61. van de Rest O, Geleijnse JM, Kok FJ, et al. Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. Neurology 2008; 71: 430-438.
62. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008; 300: 2253-2262.
63. Schneider LS. Ginkgo biloba extract and preventing Alzheimer's disease. JAMA 2008; 300: 2306-2308.
64. Le Bars PL, Katz MM, Berman N, et al. A placebocontrolled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997; 278: 1327-1332.
65. van Dongen MC, van Rossum E, Kessels AG, et al. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J Am Geriatr Soc 2000; 48: 1183-1194.
66. Schneider LS, DeKosky ST, Farlow MR, et al. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res 2005; 2: 541-551.
67. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2009:; CD003120.
68. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-881.
69. Bostom AG, Silbershatz H, Rosenberg IH, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999; 159: 1077-1080.
70. Bostom AG, Rosenberg IH, Silbershatz H, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med 1999; 131: 352-355.
71. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476-483.
72. Aisen PS, Schneider LS, Sano M, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer's disease: a randomized controlled trial. JAMA 2008; 300: 1774-1783.
73. Viswanathan A, Raj S, Greenberg SM, et al. Plasma Abeta, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial. Neurology 2009; 72: 268-272.
74. National Horizon Scanning Centre. Xaliproden (Xalprila) for Alzheimer's disease. Available at: www. haps.bham.ac.uk/publichealth/horizon/outputs/ documents/2007/april/Xaliproden.pdf. Accessed November 2009.
75. Schechter LE, Smith DL, Rosenzweig-Lipson S, et al. Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J Pharmacol Exp Ther 2005; 314: 1274-1289.
76. Douillet P, Orgogozo JM. What we have learned from the xaliproden Sanofi-Aventis trials. J Nutr Health Aging 2009; 13: 365-366.
77. Barten DM, Albright CF. Therapeutic strategies for Alzheimer's disease. Mol Neurobiol 2008; 37: 171-186.
78. Siemers ER, Quinn JF, Kaye J, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer's disease. Neurology 2006; 66: 602-604.
79. Wilcock GK, Black SE, Hendrix SB, et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol 2008; 7: 483-493.
80. TM in Alzheimer's disease. Flurizan fails to achieve significance on either co-primary endpoint; company has decided to discontinue its development of Flurizan. Available at: http://www.myriad. com/news/release/1170283. Accessed 30 April, 2009.
81. Green RC, Schneider LS, Hendrix S, et al. Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: results from an 18-month multicenter phase 3 trial. Alzheimers Dement 2008; 4(Suppl 1): T165.
82. Saumier D, Aisen PS, Gauthier S, et al. Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (tramiprosate) experience. J Nutr Health Aging 2009; 13: 370-372.
83. Alzheimer Research Forum. FDA deems U.S. Alzhemed trial results inconclusive. Available at: http://www.alzforum.org/new/detail.asp?id=1647. Accessed November 2009.
84. Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64: 1553-1562.
85. Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer's disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9: 448-452.
86. Elan. Elan and Wyeth to initiate phase 3 clinical trial of bapineuzumab (AAB-001) in Alzheimer's disease. Available at: http://www.elan. com/news/2007/20070521.asp.
87. Relkin NR, Szabo P, Adamiak B, et al. 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer's disease. Neurobiol Aging 2009; 30: 1728-1736.
88. Wyeth/Elan. Elan and Wyeth announce encouraging top-line results from phase 2 clinical trial of bapineuzumab for Alzheimer's disease. Available at: http://www.wyeth.com/news?nav=display& navTo=/wyeth html/home/news/ pressreleases/2008/ 1213683456273.html.
89. Wyeth/Elan. Elan and Wyeth plan to amend bapineuzumab phase 3 protocols. Available at: http:// www.wyeth.com/news?nav=display&navTo=/wyeth html/home/news/pressreleases/2009/1238676245463. html.
90. Pfeifer M, Boncristiano S, Bondolfi L, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002; 298: 1379.
91. Vlassara H, Cai W, Crandall J, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A 2002; 99: 15596-15601.
92. Sasaki N, Toki S, Chowei H, et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res 2001; 888: 256-262.
93. Chen X, Walker DG, Schmidt AM, et al. RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med 2007; 7: 735-742.
94. Lermontova NN, Lukoyanov NV, Serkova TP, et al. Dimebon improves learning in animals with experimental Alzheimer's disease. Bull Exp Biol Med 2000; 129: 544-546.
95. Grigorev VV, Dranyi OA, Bachurin SO. Comparative study of action mechanisms of Dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull Exp Biol Med 2003; 136: 474-477.
96. Lermontova NN, Redkozubov AE, Shevtsova EF, et al. Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels. Bull Exp Biol Med 2001; 132: 1079-1083.
97. Bachurin SO, Shevtsova EP, Kireeva EG, et al. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci 2003; 993: 334-344.
98. Doody RS, Gavrilova SI, Sano M, et al. Effect of Dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008; 372: 207-215.
99. Salehi A, Delcroix JD, Belichenko PV, et al. Increased APP expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 2006; 51: 29-42.
100. Kromer LF. Nerve growth factor treatment after brain injury prevents neuronal death. Science 1987; 235: 214-216.
101. Fischer W, Wictorin K, Bjorklund A, et al. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 1987; 329: 65-68.
102. Conner JM, Darracq MA, Roberts J, Tuszynski MH. Nontropic actions of neurotrophins: subcortical nerve growth factor gene delivery reverses agerelated degeneration of primate cortical cholinergic innervation. Proc Natl Acad Sci U S A 2001; 98: 1941-1946.
103. Eriksdotter Jonhagen M, Nordberg A, Amberla K, et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 1998; 9: 246-257.
104. Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer's disease. Nat Med 2005; 11: 551-555.
105. Alzforum. Drugs in clinical trials: Cere-110. Available at: http://www.alzforum.org/dis/tre/drc/default. asp?type=drugName&drugName= cere. Accessed November 2009.
106. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425: 191-196.
107. Wood JG, Rogina B, Lavu S, et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004; 430: 686-689.
108. Pearson KJ, Baur JA, Lewis KN, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 2008; 8: 157-168.
109. Wang J, Ho L, Zhao Z, et al. Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. FASEB J 2006; 20: 2313-2320.
110. Karuppagounder SS, Pinto JT, Xu H, et al. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int 2009; 54: 111-118.
111. Terry RD. Tangles precede plaques but don't cause them. Neurobiol Aging 2004; 25: 741-742.
112. Haroutunian V, Davies P, Vianna C, et al. Tau protein abnormalities associated with the progression of Alzheimer's disease type dementia. Neurobiol Aging 2007; 28: 1-7.
113. Murayama S, Saito Y. Neuropathological diagnostic criteria for Alzheimer's disease. Neuropathology 2004; 24: 254-260.
114. Geschwind DH. Tau phosphorylation, tangles, and neurodegeneration: the chicken or the egg? Neuron 2003; 40: 457-460.
115. Sun X, Sato S, Murayama O, et al. Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci Lett 2002; 321: 61-64.
116. Michaelis ML, Ansar S, Chen Y, et al. β-Amyloidinduced neurodegeneration and protection by structurally diverse microtubule-stabilizing agents. J Pharmacol Exp Ther 2005; 312: 659-668.
117. Butler D, Bendiske J, Michaelis ML, et al. Microtubulestabilizing agent prevents protein accumulationinduced loss of synaptic markers. Eur J Pharmacol 2007; 562: 20-27.
118. Wischik CM, Edwards PC, Lai RY, et al. Selective inhibition of Alzheimer's disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A 1996; 93: 11213-11218.
119. Atamna H, Nguyen A, Schultz C, et al. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J 2008; 22: 703-712.
120. Gura T. Hope in Alzheimer's fight emerges from unexpected places. Nat Med 2008; 14: 894.
121. Cummings JL. Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Establishing a national biomarker database: utility and incentives. Alzheimers Dement 2009; 5: 108-113.
122. Aisen PS. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Facilitating Alzheimer's disease drug development in the United States. Alzheimers Dement 2009; 5: 125-127.
123. Rowe JC, Elling M, Hazlewood J, Zakhary R. A cure for clinical trials. McKinsey Q 2002; 134-141.
124. Kolata G. 40 years war: lack of study volunteers hobbles cancer fight. New York Times August 3, 2009.
125. Physician Study: Final Report. Chicago, IL: Alzheimer's Association; 2007.
126. 2008 highlights: International Conference on Alzheimer's Disease. Available at: https://www.alz.org/ icad/icad 08highlights.asp. Accessed November 2009.